Biofrontera (BFRI) Stock Price, News & Analysis

Company Overview

Biofrontera AG is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies in dermatology. Established in 1997 and headquartered in Leverkusen, Germany, the company concentrates its efforts on photodynamic therapy (PDT) for the treatment of actinic keratosis and other skin conditions. Biofrontera’s core technology revolves around the use of aminolevulinic acid (ALA) formulations that selectively target abnormal cells, offering a non-invasive alternative to traditional surgical procedures.

The company’s flagship product, Ameluz, is an ALA-based gel approved by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for lesion-directed PDT. To complement Ameluz, Biofrontera markets proprietary light-emitting devices, including the BF-RhodoLED® lamp in Europe and the BLU-U® system in the United States, designed to activate the photosensitizer and enhance therapeutic outcomes. These products are supported by clinical data demonstrating efficacy and safety in the treatment of actinic keratosis and basal cell carcinoma lesions.

Biofrontera serves a global customer base through its European operations and a subsidiary in the United States, Biofrontera Inc., located in Wilmington, Delaware. The company has forged strategic partnerships and licensing agreements to strengthen its market presence, including collaborations for distribution in Canada, Latin America, and parts of Asia. Continued engagement with regulatory authorities underscores Biofrontera’s commitment to expanding its product approvals and securing reimbursement pathways in key markets.

Under the leadership of Chief Executive Officer Dr. Andreas Wolf and Chief Financial Officer Daniel Otto, Biofrontera pursues a growth strategy centered on pipeline diversification and international expansion. The management team combines scientific expertise with commercial acumen, aiming to introduce next-generation PDT solutions and to explore new dermatological indications. The company maintains active R&D programs and seeks collaboration opportunities to bolster its long-term position in the dermatology segment.

Key Stats

• Today's Range: $0.80 to $0.89
• 50-Day Range: $0.57 to $0.86
• 52-Week Range: $0.54 to $2.22
• Volume: 418,985 shs
• Average Volume: 953,213 shs
• Market Capitalization: $8.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.75
• Consensus Rating: Buy

Biofrontera Stock Analysis - MarketRank™

Biofrontera scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Biofrontera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biofrontera has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biofrontera are expected to grow in the coming year, from ($3.01) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biofrontera is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biofrontera is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biofrontera has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.26% of the float of Biofrontera has been sold short.

Short Interest Ratio / Days to Cover

Biofrontera has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biofrontera has recently decreased by 48.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biofrontera does not currently pay a dividend.

Dividend Growth

Biofrontera does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.26% of the float of Biofrontera has been sold short.

Short Interest Ratio / Days to Cover

Biofrontera has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biofrontera has recently decreased by 48.47%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Biofrontera has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Biofrontera this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for BFRI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biofrontera insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Biofrontera is held by insiders.

Percentage Held by Institutions

Only 10.08% of the stock of Biofrontera is held by institutions.

BFRI Stock Analysis - Frequently Asked Questions

How have BFRI shares performed this year?

Biofrontera's stock was trading at $1.09 at the beginning of 2025. Since then, BFRI shares have decreased by 21.1% and is now trading at $0.86.

How were Biofrontera's earnings last quarter?

Biofrontera Inc. (NASDAQ:BFRI) posted its earnings results on Thursday, May, 15th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.33. The business had revenue of $8.59 million for the quarter, compared to analysts' expectations of $10.55 million. Biofrontera had a negative trailing twelve-month return on equity of 305.13% and a negative net margin of 30.33%.
Read the conference call transcript.

When did Biofrontera's stock split?

Biofrontera's stock reverse split on the morning of Wednesday, July 5th 2023.The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Biofrontera IPO?

Biofrontera (BFRI) raised $19 million in an IPO on Friday, October 29th 2021. The company issued 3,100,000 shares at $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO.

How do I buy shares of Biofrontera?

Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biofrontera own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NVIDIA (NVDA), NIO (NIO) and Meta Platforms (META).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BFRI
• CIK: 1858685
• Web: www.biofrontera-us.com
• Phone: 781-245-1325
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Biofrontera: $2.75
• High Price Target: $2.75
• Low Price Target: $2.75
• Potential Upside/Downside: +219.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.76 million
• Net Margins: -30.33%
• Pretax Margin: -30.28%
• Return on Equity: -305.13%
• Return on Assets: -82.67%

Debt

• Debt-to-Equity Ratio: 8.99
• Current Ratio: 1.40
• Quick Ratio: 0.80

Sales & Book Value

• Annual Sales: $37.32 million
• Price / Sales: 0.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 9,450,000
• Free Float: 9,333,000
• Market Cap: $8.13 million
• Optionable: No Data
• Beta: 0.43